MedPath

The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults

Not Applicable
Completed
Conditions
Impairment of Oral Perception
Insulin Resistance
Interventions
Dietary Supplement: Sucrose
Dietary Supplement: Sucralose + Sucrose
Dietary Supplement: Sucralose
Dietary Supplement: Sucralose + maltodextrin
Registration Number
NCT02335021
Lead Sponsor
Yale University
Brief Summary

The purpose of this study is to investigate the effects of dietary exposure to artificial sweeteners on taste sensitivity, preference and brain response in adults. The investigators hypothesize that dietary exposure to artificial sweeteners (sucralose) will decrease sensitivity to taste, shift preference of sweet and savory taste to a higher dose, and reduce brain response in amygdala to sweet taste compared to sucrose.

Detailed Description

We aim to identify neural factors that contribute to taste intensity perception in humans and to determine environmental mechanisms that contribute to variation in taste sensitivity. Significant controversy surrounds the possibility that consumption of artificial sweeteners (AFS) leads to weight gain. Given that the five FDA approved AFSs are found in thousands of foods (Yang 2010) this marks a clear and significant gap in knowledge. Our preliminary data demonstrate a 3-fold decrease in sweet taste sensitivity following consumption of a beverage sweetened with two packets of Splenda for just 10 days. These data provide strong evidence that repeated exposure to sucralose reduces perception of sweet taste intensity, most likely by down-regulation of the sweet taste receptor. Therefore, it is imperative that we gain a greater understanding of the physiological consequences of AFS, since alterations in sweet taste perception, metabolism and brain reward that occur in response to AFS exposure may promote weight gain.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
97
Inclusion Criteria
  • Healthy
  • Fluent in English
  • Right handed
Read More
Exclusion Criteria
  • History of oral nerve damage,
  • presence of known taste or smell disorder,
  • food allergies or sensitivities (for example nuts, lactose, artificial sweeteners),
  • history of CNS disease,
  • diabetes,
  • history of DSM-IV major psychiatric disorder,
  • including alcohol and substance abuse,
  • chronic use of medication that may affect taste,
  • conditions that may interfere with gustatory or olfactory perception (colds, seasonal allergies,
  • recent smoking history),
  • aberrant stimulus ratings,
  • contra-indication for fMRI,
  • uncomfortable swallowing in supine position,
  • discomfort or anxiety associated with insertion an intravenous catheter,
  • regular artificial sweetener use.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SucroseSucroseParticipants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
Sucralose + SucroseSucralose + SucroseParticipants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + sucrose.
SucraloseSucraloseParticipants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
Sucralose + maltodextrinSucralose + maltodextrinParticipants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + maltodextrin .
Primary Outcome Measures
NameTimeMethod
Ratings of taste sensitivityup to one week after intervention

general labeled magnitude scale ratings of taste intensity

Secondary Outcome Measures
NameTimeMethod
Ad libitum food intakeup to one week after intervention

amount of Mac\&Cheese consumed

brain response to taste stimuliup to one week after intervention

BOLD response as measured by fMRI

Trial Locations

Locations (1)

Yale University

🇺🇸

New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath